Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
about
Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and PrognosticationMolecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineHeparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myelomaHeparanase regulates thrombosis in vascular injury and stent-induced flow disturbanceHeparanase regulates levels of syndecan-1 in the nucleus.Heparanase and hepatocellular carcinoma: promoter or inhibitor?Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.Versatile role of heparanase in inflammationInput of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.Heparanase cooperates with Ras to drive breast and skin tumorigenesisHeparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLProteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancerMammalian heparanase: what is the message?SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma.The glycome of normal and malignant plasma cellsHeparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotypePrognostic significance of syndecan-1 expression in cervical cancers.Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasiasShed syndecan-2 enhances tumorigenic activities of colon cancer cells.Genetic and epigenetic inactivation of extracellular superoxide dismutase promotes an invasive phenotype in human lung cancer by disrupting ECM homeostasis.Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinomaCharacterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma.Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasisThe endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymesProteoglycans in cancer biology, tumour microenvironment and angiogenesis.Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept.Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applicationsThe molecular characterization and clinical management of multiple myeloma in the post-genome era.Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myelomaSyndecan-1: a dynamic regulator of the myeloma microenvironment.Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease.The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorInhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
P2860
Q26784262-BE3B6BBC-1AA4-4E5C-A66B-FD6C7CFB0372Q26796247-95779710-3096-4049-A669-1FDB7C9C89E0Q27001749-67157172-F4CB-459D-B281-D2E99C4DF815Q28264895-C96EEAAD-D39D-488F-823E-EA86B74C2109Q33420350-C4E9E83D-C9C8-4BC2-A7EF-69840B8325F7Q33596487-9D6F9F6F-7E7D-4CBF-8A77-444044161168Q33748979-D5EF4912-DD30-4394-9B29-1870CF9022E3Q33754644-E1B2BAD5-50C4-443B-8C79-2511CB94A88AQ33770777-9C24FA22-08BB-46AF-801C-7B2BC1241C76Q34022979-CFB035A3-8317-424B-AC78-E99474C626E7Q34052534-6B342C1B-D8C7-47B3-93CB-0BD0FC3228FAQ34267974-A37456AA-F934-412A-80E5-AEDDC307723FQ34398151-0ACE2B52-9A57-44A9-B625-F351394518D2Q34448984-AA4E51B0-040C-45CA-BA19-387F69709104Q34499650-D42B2AF2-5C92-45AB-80E8-255338F8BE46Q34652072-B4FEBA24-3B4C-4051-BB2D-2CB9D71559BFQ34694466-018BBD27-BAD2-4C2D-AB61-535575C63D4EQ34762351-66D4E59E-6FBC-4108-8458-1A8C9FC8D819Q35080602-1CE3A31B-0675-472F-A8DA-154462A6D3DEQ35182839-21D1E114-21E8-4C7F-AC53-CE19539DEC99Q35285294-B58A8FFB-436A-4CC4-8965-F2D583E5104CQ35462258-4EEC32FA-EC5B-4905-B21A-0DD11EE84566Q35551894-A2286713-F66E-4BF1-A04F-1A1BE91B5597Q35683231-23E91B99-948E-4781-A994-83F7CC682F69Q35801303-81FB8974-1753-4319-8ABA-0A8AE8E0B4FAQ35921509-45D3FEB8-3154-41BD-8A08-5C166EDD70E9Q35990705-DF093878-B708-499E-A951-E02F3EA0D5D9Q36260612-5ACF6738-05D5-4F61-BBD6-FF9E10F16395Q36436089-89C60D0B-D4C3-4AE7-AAE7-F46442C201FCQ36498218-C83F4E64-B7BE-40F0-89FF-1A2E051B185DQ36739082-D94A1ABB-B38A-4345-A73E-0F2ADA67AC96Q36787608-962FC924-3A98-4FDE-91FE-143EA5C55FD0Q36884215-7566270A-8806-4C7D-9568-91816FE2DB5CQ36919158-C31C66D4-4B6B-41E3-8F03-9E2A52C2F96FQ36939043-66987C5D-2F2D-46E0-8EDD-C5926FA765E6Q36973696-EBEDFB7E-4DD4-4970-848F-2510458C589CQ37008599-F1590A29-AA46-47AB-9842-E0CE1237B129Q37204761-1F034A5A-7888-4363-924B-C2580D767617Q37215171-01D5DF0E-FE86-4D76-969A-7E10788B688FQ37237509-324F5565-45C0-4AD0-9BDB-EEBA24BBBB78
P2860
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Heparanase influences expressi ...... ic factor in multiple myeloma.
@ast
Heparanase influences expressi ...... ic factor in multiple myeloma.
@en
type
label
Heparanase influences expressi ...... ic factor in multiple myeloma.
@ast
Heparanase influences expressi ...... ic factor in multiple myeloma.
@en
prefLabel
Heparanase influences expressi ...... ic factor in multiple myeloma.
@ast
Heparanase influences expressi ...... ic factor in multiple myeloma.
@en
P2093
P2860
P1433
P1476
Heparanase influences expressi ...... ic factor in multiple myeloma.
@en
P2093
Bernard Klein
Eric Jourdan
Jean-Francois Rossi
John De Vos
Karène Mahtouk
Marion Baudard
Marion Larroque
Michael Hundemer
Michel Jourdan
Pierre Raynaud
P2860
P304
P356
10.1182/BLOOD-2006-08-043232
P407
P577
2007-03-05T00:00:00Z